Related Experiment Videos
Immediate breast reconstruction and high-dose chemotherapy
P Rey1, G Martinelli, J Y Petit
1Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. prey@arsmedica.ch
Annals of Plastic Surgery
|August 18, 2005
Summary
Immediate breast reconstruction (IBR) after mastectomy is safe and does not delay high-dose chemotherapy (HDCT). However, HDCT increases the risk of late infections following IBR, necessitating careful preoperative evaluation and prevention of contamination.
Area of Science:
- Oncology
- Plastic Surgery
- Breast Cancer Treatment
Background:
- Immediate breast reconstruction (IBR) is a safe procedure for most mastectomy patients, including those with locally advanced breast cancer.
- However, the safety and impact of IBR in conjunction with high-dose chemotherapy (HDCT) require further evaluation.
Purpose of the Study:
- To assess the risk of chemotherapy delay due to surgical complications after IBR.
- To evaluate the risk of late surgical complications when IBR is combined with HDCT.
Main Methods:
- Retrospective review of 105 patients undergoing mastectomy between October 1999 and January 2002.
- Patients were divided into three groups: IBR with HDCT (23), IBR with conventional CT (67), and mastectomy alone with HDCT (15).
- Reconstructive techniques included permanent prosthesis and temporary expanders; flap reconstructions were excluded for homogeneity.
Main Results:
- No significant delay in HDCT administration was observed in patients who underwent IBR (54 days vs. 60 days, P=0.13).
- Early complication rates (before CT) were low at 2.9% (infections).
- Late complication rates (after CT) were significantly higher in the IBR + HDCT group (39%) compared to IBR + conventional CT (20%).
Conclusions:
- IBR does not impede the initiation of HDCT after mastectomy.
- While early complication rates are comparable to literature, late infections are more frequent after HDCT, likely due to chemotherapy-induced immune suppression.
- IBR with HDCT is oncologically safe but carries a higher risk of post-reconstruction complications, warranting careful infection risk assessment and prevention.